GenomeFrontier selects BioCina to help make cancer therapy products

GenomeFrontier Therapeutics AU has partnered with BioCina for a project to develop products for gene therapy cancer treatments.

The partnership will see BioCina support GenomeFrontier AU with the process development and therapeutic goods manufacturing practices and standards for Minicircle DNA and Plasmid DNA, which are virus-free chimeric antigen receptor T cell products (CAR-T).

GenomeFrontier AU, the Australian arm of Genome Frontier Therapeutics Inc. which is headquartered in Taiwan, will leverage the company’s virus-free cell and gene engineering platforms and its ‘Quantum Engine’ cell engineering systems to make the CAR-T cell therapy products for use in a Phase 1 clinical trial.

Genome Frontier said its ‘Quantum Engine’ comprises four proprietary platforms, which improve vector delivery, therapeutic gene integration, cell expansion capacity, and gene design.

BioCina’s CEO, Mark W. Womack, said BioCina is thrilled to be GenomeFrontier’s partner for the cancer treatment program, utilizing both Minicircle and Plasmid DNA,

GenomeFrontier’s founder and CEO, Sareina Wu added, “We believe that a cancer-free world is not only possible but is more real than ever before, due to major advancements in gene therapy. “